Dr Dulce Socorro Urena, MD | |
720 Northern Blvd, C.w. Post-long Island University Student Health Service, Greenvale, NY 11548-1319 | |
(516) 299-2345 | |
(516) 299-4113 |
Full Name | Dr Dulce Socorro Urena |
---|---|
Gender | Female |
Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
Location | 720 Northern Blvd, Greenvale, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1922211804 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | 177275 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Dulce Socorro Urena, MD 720 Northern Blvd, C.w. Post-long Island University Student Health Service, Greenvale, NY 11548-1319 Ph: (516) 299-2345 | Dr Dulce Socorro Urena, MD 720 Northern Blvd, C.w. Post-long Island University Student Health Service, Greenvale, NY 11548-1319 Ph: (516) 299-2345 |
News Archive
Health professionals require more guidance to prepare and support children when a parent is dying, a new study in the journal Palliative Medicine reports.
Today, Baptist Health and American Family Care announced that they have partnered to provide primary and urgent care services throughout Central Alabama.
Exposure to dirty air is linked to decreased function of a gene that appears to increase the severity of asthma in children, according to a joint study by researchers at Stanford University and the University of California, Berkeley.
"With donor support flagging around the world, U.S. leadership is crucial. Congress must fully fund its global health programs, especially the Global Fund" to Fight AIDS, Tuberculosis and Malaria, Joyce Kamwana, a Global Fund "HERE I AM" campaign ambassador, writes in The Hill's "Congress Blog."
Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.
› Verified 7 days ago